- Alarm and Monitoring Systems
- Temperature Control Systems
Biobanking Market Size is valued USD x billion in 2021 and is expected to reach USD x billion by 2028, growing at a CAGR od x% during the forecast 2022-2028. Biobank is referred to the type of biorepository which stores the biological samples such as DNA, blood, human tissue that is intended for use in research. The biobanks play a vital role in the medical research. Biobanks acts as the important resources in the development of new drugs. The samples in biobanks can often be used by multiple researchers for their research studies. The biological banks keep a record of the health related information for the use in the health and medical research. It is also used in the detection of the various diseases, their causes. In October 2017, Brooks Automation, Inc. has acquired 4titude, Ltd., a privately-held manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of Infant nutritionKey Development: In Mar 2022, Centogene N.V. expanded its collaboration agreement with Pfizer Inc. The initial agreement, which gave Pfizer access to relevant data from CENTOGENE's Bio/Databank, was signed in 2019 with the goal of accelerating the discovery and validation of novel genetic targets as candidates for the development of new medicines for rare diseases.Â A new collaborative research initiative has been launched, with the goal of validating rare genetic origins of neurodegenerative illnesses as prospective therapeutic targets. Â In Sept 2021, STEMCELL Technologies collaborated with WiCell and launched human pluripotent stem cell characterization and banking services. The new services complement STEMCELL's existing line of pluripotent stem cell research products, which includes mTeSR Plus and mTeSR1, the world's most commonly published feeder-free hPSC maintenance medium.
Fastest Growing Market
Increasing chronic disorders is the major factor driving the growth of the biobanking market. The developing technology is also adding fuel for the growth of the biobanking market. The biobanks play a major role in the development of new drugs which likely to drive the growth of the market. The demand for the personalized medications, which are associated with minimal side effects prompting the patient population to approach for the personalized medications, which is likely to drive the growth of the biobanking market. The increasing healthcare expenditure and the developing healthcare infrastructure aiding the growth of the biobanking market. However, the high cost of the techniques is expected to hamper the growth of the market. The dearth of skilled healthcare professionals and handling issues related to biobanks maintenance is expected to hindering the growth of the market over the forecast period.
The CAGR of the biobanking market is x% over the forecast period (2022 - 2028)
Thermo Fisher Scientific Inc, Tecan AG, Beckman Coulter, Inc., VWR International, LLC, Qiagen N.V.
The Asia Pacific is the fastest-growing region for the bio-banking market
Some of the players in the global biobanking market include: